|
Thermo Fisher
gene exp fgf4 hs00173564 m1 ![]() Gene Exp Fgf4 Hs00173564 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pmc06428113-269-53--1?v=Thermo+Fisher Average 88 stars, based on 1 article reviews
gene exp fgf4 hs00173564 m1 - by Bioz Stars,
2026-07
88/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp fgf4 mm00438916 g1 ![]() Gene Exp Fgf4 Mm00438916 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pmc03929414-194-13--1?v=Thermo+Fisher Average 87 stars, based on 1 article reviews
gene exp fgf4 mm00438916 g1 - by Bioz Stars,
2026-07
87/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp fgf4 mm00438917 m1 ![]() Gene Exp Fgf4 Mm00438917 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pmc10292157-406-56-18?v=Thermo+Fisher Average 86 stars, based on 1 article reviews
gene exp fgf4 mm00438917 m1 - by Bioz Stars,
2026-07
86/100 stars
|
Buy from Supplier |
|
Collateral Therapeutics
bfgf gene therapy ![]() Bfgf Gene Therapy, supplied by Collateral Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pm39105478-230-15-0?v=Collateral+Therapeutics Average 90 stars, based on 1 article reviews
bfgf gene therapy - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Angionetics Inc
fgf-4 gene therapy ![]() Fgf 4 Gene Therapy, supplied by Angionetics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pmc06493298-76-0-7?v=Angionetics+Inc Average 90 stars, based on 1 article reviews
fgf-4 gene therapy - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp fgf4 rn00709728 m1 ![]() Gene Exp Fgf4 Rn00709728 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/pm18429950-87-16--1?v=Thermo+Fisher Average 86 stars, based on 1 article reviews
gene exp fgf4 rn00709728 m1 - by Bioz Stars,
2026-07
86/100 stars
|
Buy from Supplier |
|
Berlex Laboratories Inc
adenovirus mediated human fgf-4 gene transfer ![]() Adenovirus Mediated Human Fgf 4 Gene Transfer, supplied by Berlex Laboratories Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fgf4+gene/10__1089_slash_blr__1999__18__45-441-14-33?v=Berlex+Laboratories+Inc Average 90 stars, based on 1 article reviews
adenovirus mediated human fgf-4 gene transfer - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Full length Clone DNA of Human fibroblast growth factor 4
|
Buy from Supplier |
|
Full length Clone DNA of Human fibroblast growth factor 4 with C terminal HA tag
|
Buy from Supplier |
|
FGF4 KN2 0 Human gene knockout kit via CRISPR non homology mediated
|
Buy from Supplier |
|
Full length Clone DNA of Mouse fibroblast growth factor 4
|
Buy from Supplier |
|
Full length Clone DNA of Human fibroblast growth factor 4 with C terminal GFPSpark tag
|
Buy from Supplier |
Image Search Results
Journal: Integrative Biology
Article Title: Rapid translocation of pluripotency-related transcription factors by external uniaxial forces
doi: 10.1093/intbio/zyz003
Figure Lengend Snippet: Molecular characterization and identification of 10% strain applied human ESCs for 2 h via qRT-PCR analysis for temporal expression of (A) pluripotency (NANOG, OCT4, SOX2, and KLF4), (B) trophoctoderm markers (CDX2, EOMES, EpCAM, and FGF4), (C) ecto- and endodermal lineage differentiation (WNT3A, SOX17, GATA6, and PAX6), and (D) cytoskeletal, focal adhesion kinase (Ptk2) and PXN (Paxillin), Integrin alpha 6 (ITGA6) and E-CADHERIN with and without 10% strain. All quantification from three independent replicates. Unpaired t test P values <0.05 (*), <0.01 (**), <0.001(***), n.s.: not significant.
Article Snippet: All primers were purchased from ThermoFisher Life Technologies. table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Gene symbol Assay ID UniGene ID NANOG Hs02387400_g1 Hs.635882 POU5F1 (OCT 3/4) Hs03005111_g1 (FAM-MGB) Hs.249184 SOX2 Hs01053049 (FAM-MGB) Hs.518438 FAK (PTK2) Hs03657683 Hs.395482 CDX2 Hs01078080_m1 Hs.127383 E-CADHERIN Hs01023894_m1 Hs.461086 PXN Hs01104424_m1 Hs.446336 EOMES Hs00172872_m1 Hs.591663 FGF4
Techniques: Quantitative RT-PCR, Expressing
Journal: Integrative Biology
Article Title: Rapid translocation of pluripotency-related transcription factors by external uniaxial forces
doi: 10.1093/intbio/zyz003
Figure Lengend Snippet: Primer sets used in qRT-PCR
Article Snippet: All primers were purchased from ThermoFisher Life Technologies. table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Gene symbol Assay ID UniGene ID NANOG Hs02387400_g1 Hs.635882 POU5F1 (OCT 3/4) Hs03005111_g1 (FAM-MGB) Hs.249184 SOX2 Hs01053049 (FAM-MGB) Hs.518438 FAK (PTK2) Hs03657683 Hs.395482 CDX2 Hs01078080_m1 Hs.127383 E-CADHERIN Hs01023894_m1 Hs.461086 PXN Hs01104424_m1 Hs.446336 EOMES Hs00172872_m1 Hs.591663 FGF4
Techniques:
Journal: Development (Cambridge, England)
Article Title: Oct4 is required for lineage priming in the developing inner cell mass of the mouse blastocyst
doi: 10.1242/dev.096875
Figure Lengend Snippet: Effect of addition of excess FGF2 or FGF4 to Oct4 -deleted IOD embryos. (A) Confocal images of two untreated IOD embryos (top two panels) and two 4-OHT-treated embryos (bottom two panels) cultured from the 8-cell stage (E2.5) for 48 hours, as indicated in , supplemented with 1 mg/ml FGF4 (or FGF2) from 24-48 hours showing Oct4 (white), Nanog (green), Sox17 (red) and DAPI (blue). (B) Average numbers of cells expressing Sox17, Nanog and total cell number. The number of embryos used for each data point is indicated beneath the x -axis. Error bars represent s.d. (C-E) Phase contrast images of whole blastocyst outgrowths from IOD embryos following 5 days in culture after (C) culture for 24 hours from the 8-cell stage with treatment, (D) 24 hours with 4-OHT, (E) 24 hours with 4-OHT and FGF2. Scale bar: 50 μm.
Article Snippet: The following TaqMan probes were used: Pou5f1, Mm03053917_g1; Nanog, Mm02019550_s1; Pdgfrα, Mm00440701_m1; Fgf4,
Techniques: Cell Culture, Expressing
Journal: Development (Cambridge, England)
Article Title: Oct4 is required for lineage priming in the developing inner cell mass of the mouse blastocyst
doi: 10.1242/dev.096875
Figure Lengend Snippet: Model of Oct4 functions during preimplantation development. As shown in , levels of Nanog protein are higher when Oct4 is subject to maternal-zygotic deletion, implying that Oct4 plays a role in restricting Nanog to maintain flexibility for formation of PrE. It is known from previous work ( ; ) that Oct4 is required to suppress Cdx2 and trophectoderm differentiation in the mid-late ICM. Single-cell expression analysis suggests that sustained expression of Oct4 beyond the 8-cell stage is required to enable the segregation of molecular programmes for either epiblast or PrE. However, expression of Sox17 can be induced by addition of excess FGF2 or FGF4, and overt differentiation of PrE derivatives is possible in cells from which Oct4 was conditionally deleted from the morula stage following ESC complementation from the 8-cell stage.
Article Snippet: The following TaqMan probes were used: Pou5f1, Mm03053917_g1; Nanog, Mm02019550_s1; Pdgfrα, Mm00440701_m1; Fgf4,
Techniques: Expressing
Journal: Journal of Market Access & Health Policy
Article Title: Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption
doi: 10.1080/20016689.2019.1600939
Figure Lengend Snippet: ATMP candidates in the industrial pipeline in phase III/IV clinical trial.
Article Snippet:
Techniques: Derivative Assay, Polymer